Abstract |
The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.
|
Authors | A B Sousa, J P Fernandes, I Costa, G Ferreira, O Nunes, P Ribeiro, A Neves, E Cruz, F Aveiro, A S Rodrigues, M Bernardo, A Conduto, A J Gonçalves, A Monteiro, M Sousa, V H Soares, J Veiga, J Gouveia |
Journal | Hematology and cell therapy
(Hematol Cell Ther)
Vol. 40
Issue 2
Pg. 63-6
(Apr 1998)
ISSN: 1269-3286 [Print] France |
PMID | 9615248
(Publication Type: Journal Article)
|
Chemical References |
- Cytarabine
- Granulocyte-Macrophage Colony-Stimulating Factor
- Mitoxantrone
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cytarabine
(administration & dosage)
- Disease-Free Survival
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(administration & dosage, adverse effects)
- Humans
- Leukemia, Myeloid
(drug therapy, mortality)
- Male
- Middle Aged
- Mitoxantrone
(administration & dosage)
- Remission Induction
(methods)
- Survival Rate
|